Amarin Corp Plc (AMRN)

[HDGabor]

r-

Obviously this is light years away

But the expected completion of the CLEAR study (an event-driven*, global, randomized, double-blind, placebo-controlled study that completed enrollment in August 2019 of 14,032 patients with hypercholesterolemia and high CVD risk at over 1,400 sites in 32 countries) is 2022 H2.

* occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease (CVD) who are only able to tolerate less than the lowest approved daily starting dose of a statin and are considered “statin averse.”

Best,
G